These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 27510721)

  • 21. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2013 Jun; 31(25):2762-71. PubMed ID: 23588088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.
    Türel O; Kisa A; McIntosh ED; Bakir M
    Value Health; 2013; 16(5):755-9. PubMed ID: 23947968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools.
    Chaiyakunapruk N; Somkrua R; Hutubessy R; Henao AM; Hombach J; Melegaro A; Edmunds JW; Beutels P
    BMC Med; 2011 May; 9():53. PubMed ID: 21569402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
    Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
    Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
    Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
    Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
    Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
    PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
    Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
    Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations.
    Løchen A; Anderson RM
    Clin Microbiol Infect; 2020 Jan; 26(1):60-70. PubMed ID: 31055164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
    Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
    BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies.
    Syeed MS; Ghule P; Le LM; Veettil SK; Horn EK; Perdrizet J; Wasserman M; Thakkinstian A; Chaiyakunapruk N
    Value Health; 2023 Apr; 26(4):598-611. PubMed ID: 36328324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review.
    Shao Y; Stoecker C
    Expert Rev Vaccines; 2020 Dec; 19(12):1141-1151. PubMed ID: 33428494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
    Treskova M; Scholz SM; Kuhlmann A
    Pharmacoeconomics; 2019 Sep; 37(9):1093-1127. PubMed ID: 31025189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.